News from bayer healthcare pharmaceuticals inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 13, 2014, 08:30 ET

Over 1,000 Medical Sites in the United States Now Licensed to Administer Xofigo® (radium Ra 223 dichloride) Injection

Bayer HealthCare Inc. today announced that, approximately one year following the national launch, over 1,000 sites in the United States have...

Jul 25, 2014, 02:30 ET

Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients with Advanced Breast Cancer

 Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary (NASDAQ: AMGN), today announced that an investigational Phase 3 trial of...

Jun 02, 2014, 09:00 ET
New Bayer Inserter for Mirena and Skyla (PRNewsFoto/Bayer HealthCare Pharmaceuticals)

Bayer HealthCare Pharmaceuticals Introduces New Bayer Inserter For Mirena® (Levonorgestrel-Releasing Intrauterine System) 52 Mg

 Bayer HealthCare Pharmaceuticals Inc. today announced Food and Drug Administration (FDA) approval of a new inserter for Mirena®. Bayer...

Apr 23, 2014, 19:02 ET
Bayer HealthCare logo (PRNewsFoto/Bayer HealthCare Pharmaceuticals)

Phase 3 DECISION Trial of NEXAVAR (sorafenib) in Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Cancer Refractory to Radioactive Iodine Published in The Lancet

 Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that The Lancet...

Mar 11, 2014, 03:30 ET
Bayer HealthCare Pharmaceuticals Inc.  (PRNewsFoto/Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary)

Bayer and Onyx Report Phase 3 Study Results of NEXAVAR® (sorafenib) as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation

 Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial...

Mar 03, 2014, 08:00 ET

Advocacy Organization Fight Colorectal Cancer and Bayer Kick-Start Colorectal Cancer Awareness Month at National Historic Landmark

To raise awareness about colorectal cancer—the nation's second leading cause of cancer-related deaths—Fight Colorectal...

Feb 20, 2014, 02:30 ET

Bayer Initiates Phase III Trial of Stivarga® (regorafenib) Tablets in Patients with Colorectal Cancer after Resection of Liver Metastases

 Bayer HealthCare today announced that the company has begun to enroll patients in the COAST trial studying Stivarga®...

Feb 18, 2014, 02:15 ET

Bayer's Long-Acting Recombinant Factor VIII Demonstrated Prophylaxis with Less Frequent Infusions in Hemophilia A in Phase III Trial

Bayer HealthCare today announced positive results from the PROTECT VIII trial evaluating the company's investigational...

Nov 22, 2013, 17:30 ET
Nov 20, 2013, 11:14 ET

Bayer's Third Annual Virtual Walk for Hemophilia Raises Funds, Brings Together the Hemophilia Community

 Bayer HealthCare and the National Hemophilia Foundation (NHF) today announced the successful conclusion of the third annual...

Oct 28, 2013, 09:51 ET

Bayer to Present Data Investigating Recently Approved Adempas® (riociguat) Tablets

 Bayer HealthCare today announced preliminary results from two ongoing, open-label, long-term extension studies investigating its recently...

Oct 08, 2013, 18:54 ET

FDA Approves Bayer's New Class of Drug Adempas® (riociguat) tablets to Treat Adults with PAH and Persistent, Recurrent or Inoperable CTEPH

Bayer HealthCare announced today that the United States Food and Drug Administration (FDA) has approved Adempas® (riociguat) tablets for: (i)...

Sep 25, 2013, 08:30 ET

Bayer's Investigational Drug Riociguat Granted FDA Orphan Drug Designation for Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension

WHIPPANY, N.J., Sept. 25, 2013 /PRNewswire/ -- Bayer HealthCare today announced that the U.S. Food and Drug Administration's (FDA)...

Sep 20, 2013, 07:40 ET

Xofigo® (radium Ra 223 dichloride) Injection Recommended for Approval in the European Union

 Bayer HealthCare announced today that the the European Committee for Medicinal Products for Human Use (CHMP) recommended Xofigo® (radium...

Aug 27, 2013, 02:30 ET

Bayer and Onyx Pharmaceuticals Announce FDA Priority Review Designation of Nexavar® (sorafenib) Supplemental New Drug Application for the Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Bayer HealthCare and Onyx Pharmaceuticals (NASDAQ: ONXX) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority...

Aug 06, 2013, 15:18 ET

FDA Advisory Committee Unanimously Recommends Approval Of Bayer's Riociguat In Two Pulmonary Hypertension Indications

 Bayer HealthCare today announced that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee...

Jul 17, 2013, 17:01 ET

The New England Journal of Medicine Publishes Results from the Phase III ALSYMPCA Study of Xofigo® (radium Ra 223 dichloride) Injection

 Bayer HealthCare today announced that data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial of...

Jul 08, 2013, 04:28 ET

Bayer Initiates Phase III Trial of an Investigational Recombinant Factor VIII Compound in Children with Hemophilia A

 Bayer HealthCare today announced the company has started to enroll patients in an international Phase II/III trial to evaluate its...

Jul 01, 2013, 02:30 ET

Bayer and Onyx Pharmaceuticals Announce Submission of FDA and EMA Applications for Nexavar® (sorafenib) for the Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer

 Bayer HealthCare and Onyx Pharmaceuticals (NASDAQ: ONXX) today announced the submission of a supplemental New Drug Application (sNDA) to the...